Cancer and Coagulation

Overview

Journal Am J Hematol

Specialty Hematology

Date 2012 Mar 6

PMID 22389165

Citations 27

Authors

Alok A Khorana

Affiliations

Soon will be listed here.

Abstract

Thromboembolism, including both venous and arterial events, occurs commonly amongst patients with cancer. The occurrence of thromboembolism has significant consequences for cancer patients, including direct and indirect associations with mortality, morbidity, requirement for long-term anticoagulant therapy and consumption of healthcare resources. Recent studies have resulted in a better understanding of clinical risk factors and biomarkers of cancer-associated thrombosis, and a risk assessment model incorporating both has now been validated in multiple settings. Thromboprophylaxis with either unfractionated heparin or low-molecular-weight heparins (LMWHs) has been shown to be safe and effective in high-risk settings such as hospitalization for medical illness and the postsurgical period. Emerging new data from randomized studies have focused on outpatient prophylaxis, suggesting potential benefits in this setting as well. Treatment of cancer-associated thrombosis requires long-term anticoagulation with LMWH. Results from ongoing and planned trials of novel anticoagulants in the cancer setting are awaited.

Citing Articles

Establishment and verification of a prognostic model based on coagulation and fibrinolysis-related genes in hepatocellular carcinoma.

Fan M, Lu L, Shang H, Lu Y, Yang Y, Wang X Aging (Albany NY). 2024; 16(9):7578-7595.

PMID: 38568089 PMC: 11131995. DOI: 10.18632/aging.205699.

Clinical guidelines for prevention and treatment of CAT in Japan and other countries.

Seki Y Int J Hematol. 2024; 119(5):505-515.

PMID: 38558108 DOI: 10.1007/s12185-024-03736-w.

Lung cancer presenting with acute myocardial infarction and pulmonary embolism within 1 month.

Jin J, Qi X, Zhang H, Li M, Li S, Shen G SAGE Open Med Case Rep. 2023; 11:2050313X231181979.

PMID: 37434900 PMC: 10331209. DOI: 10.1177/2050313X231181979.

Smoking and Activated Clotting Time during coronary angiography and angioplasty: protocol for the ACT-Tobacco trial.

Trimole R, Manzi H, Hosseini K, Remen T, Toussaint-Hacquard M, Camenzind E Res Pract Thromb Haemost. 2023; 7(2):100083.

PMID: 36915865 PMC: 10005900. DOI: 10.1016/j.rpth.2023.100083.

Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.

Khorana A, Palaia J, Rosenblatt L, Pisupati R, Huang N, Nguyen C J Immunother Cancer. 2023; 11(1).

PMID: 36657815 PMC: 9853260. DOI: 10.1136/jitc-2022-006072.

References

Khorana A . Venous thromboembolism and prognosis in cancer. Thromb Res. 2010; 125(6):490-3. PMC: 2878879. DOI: 10.1016/j.thromres.2009.12.023. View

Moore R, Adel N, Riedel E, Bhutani M, Feldman D, Tabbara N . High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011; 29(25):3466-73. PMC: 6815979. DOI: 10.1200/JCO.2011.35.5669. View

Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P . A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. 1998; 338(7):409-15. DOI: 10.1056/NEJM199802123380701. View

Samama M, Cohen A, Darmon J, Desjardins L, Eldor A, Janbon C . A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999; 341(11):793-800. DOI: 10.1056/NEJM199909093411103. View

Kucher N, Koo S, Quiroz R, Cooper J, Paterno M, Soukonnikov B . Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005; 352(10):969-77. DOI: 10.1056/NEJMoa041533. View

Kakkar V, Balibrea J, Martinez-Gonzalez J, Prandoni P . Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost. 2010; 8(6):1223-9. DOI: 10.1111/j.1538-7836.2010.03892.x. View

Khorana A, Francis C, Culakova E, Fisher R, Kuderer N, Lyman G . Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006; 24(3):484-90. DOI: 10.1200/JCO.2005.03.8877. View

Zwicker J, Liebman H, Neuberg D, Lacroix R, Bauer K, Furie B . Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res. 2009; 15(22):6830-40. PMC: 2783253. DOI: 10.1158/1078-0432.CCR-09-0371. View

Thaler J, Ay C, Mackman N, Bertina R, Kaider A, Marosi C . Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost. 2012; 10(7):1363-70. DOI: 10.1111/j.1538-7836.2012.04754.x. View

10.

Vormittag R, Simanek R, Ay C, Dunkler D, Quehenberger P, Marosi C . High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. Arterioscler Thromb Vasc Biol. 2009; 29(12):2176-81. DOI: 10.1161/ATVBAHA.109.190827. View

11.

Nalluri S, Chu D, Keresztes R, Zhu X, Wu S . Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008; 300(19):2277-85. DOI: 10.1001/jama.2008.656. View

12.

Lyman G, Khorana A, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M . American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007; 25(34):5490-505. DOI: 10.1200/JCO.2007.14.1283. View

13.

Agnelli G, Gussoni G, Bianchini C, Verso M, Mandala M, Cavanna L . Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009; 10(10):943-9. DOI: 10.1016/S1470-2045(09)70232-3. View

14.

Ay C, Dunkler D, Marosi C, Chiriac A, Vormittag R, Simanek R . Prediction of venous thromboembolism in cancer patients. Blood. 2010; 116(24):5377-82. DOI: 10.1182/blood-2010-02-270116. View

15.

Rasmussen M, Jorgensen L, Wille-Jorgensen P, Nielsen J, Horn A, Mohn A . Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost. 2006; 4(11):2384-90. DOI: 10.1111/j.1538-7836.2006.02153.x. View

16.

Wagman L, Baird M, Bennett C, Bockenstedt P, Cataland S, Fanikos J . Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2008; 6(8):716-53. DOI: 10.6004/jnccn.2008.0055. View

17.

Choueiri T, Schutz F, Je Y, Rosenberg J, Bellmunt J . Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010; 28(13):2280-5. DOI: 10.1200/JCO.2009.27.2757. View

18.

Khorana A, Kuderer N, Culakova E, Lyman G, Francis C . Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008; 111(10):4902-7. PMC: 2384124. DOI: 10.1182/blood-2007-10-116327. View

19.

Kroger K, Weiland D, Ose C, Neumann N, Weiss S, Hirsch C . Risk factors for venous thromboembolic events in cancer patients. Ann Oncol. 2005; 17(2):297-303. DOI: 10.1093/annonc/mdj068. View

20.

Elting L, Escalante C, Cooksley C, Avritscher E, Kurtin D, Hamblin L . Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med. 2004; 164(15):1653-61. DOI: 10.1001/archinte.164.15.1653. View